FDA Approves Genentech Medicine for Women with Platinum-Resistant Recurrent Ovarian Cancer
November 14th, 2014
On November 14, 2014, the FDA approved Avastin® (bevacizumab) in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.
News in brief
- Women with a specific type of platinum-resistant ovarian cancer now have the option of Avastin in combination with chemotherapy
- In a Phase III trial, Avastin plus chemotherapy reduced the risk of disease worsening or death (progression-free survival or PFS) by 62 percent compared to women who received chemotherapy alone
- Avastin plus chemotherapy is the first treatment option for women with this type of ovarian cancer in more than 15 years
- Avastin is approved in the United States to treat six distinct tumor types
Supporting Information
“Avastin plus chemotherapy is the first new treatment option for women with this difficult-to-treat type of ovarian cancer in more than 15 years. Risk of the disease worsening was reduced by 62 percent for women who received Avastin plus chemotherapy in the study, and a notable treatment effect was observed with paclitaxel, which may be important when choosing treatment.”